Skip to main content
. 2015 May 12;6(24):20474–20484. doi: 10.18632/oncotarget.4105

Figure 4. ICRF187 and ICRF193 inhibit prostate cancer cell growth and delay cell cycling at the G2/M phase.

Figure 4

(A) LNCaP, LNCaP95, MR49F, 22RV1, PC3 and DU145 cells were cultured in mediums containing 5% CSS for 48 hours. Cells were treated with vehicle, ENZ, 10uM of ICRF187 or 1uM of ICRF193 for 0-7 days. The dose of ENZ was 1uM in LNCaP, 5uM in LNCaP95 and 22RV1 cells and 10uM in MR49F cells. MTS assays were measured the relative cell growth rates to day 0. Results were from three independent experiments (n = 6/repeat). (B) LNCaP and LNCaP95 cells were serum starved for 12 hours and then replenished with culture medium containing serum. Treatments of vehicle, 10uM of ICRF187 or 2uM of ICRF193 were also applied to LNCaP cells for 1.5 hours or to LNCaP95 cells for 2 hours. (C) LNCaP and LNCaP95 cells were cultured in growth medium containing 100 ng/ml nocodazole in addition to vehicle, 10uM of ICRF187 or 2uM of ICRF193 for 12 hours. Cells were then replenished with nocodazole free medium containing vehicle, 10uM of ICRF187 or 2uM of ICRF193 for LNCaP cells for 1.5 hours or for LNCaP95 cells 2 hours. Cells were collected and used for FACS assays to determine cell populations at G0/G1, S and G2/M phases (B-C). Results were repeated from two independent experiments (n = 3/repeat). One-way ANOVA followed by student t-test was performed with P < 0.001 as ***.